# Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

> **NCT01019876** · PHASE2,PHASE3 · COMPLETED · sponsor: **Columbia University** · enrollment: 38 (actual)

## Conditions studied

- Bone Marrow Failure
- Osteopetrosis
- Fanconi Anemia
- Severe Combined Immunodeficiency

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Busulfan
- **DRUG:** Alemtuzumab
- **DRUG:** Rabbit Anti-thymocyte Globulin
- **DRUG:** Horse Anti-thymocyte Globulin

## Key facts

- **NCT ID:** NCT01019876
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2021-09-07
- **Final completion:** 2021-09-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019876, "Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01019876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*